SynVivo is a spin-out company from CFDRC that has developed a microchip platform that provides a physiologically realistic microfluidic environment that allows the real-time study of cellular behavior and drug delivery. SynVivo recreates the complex in vivo vasculature including scale, morphology, fluidics and cellular interactions in an in vitro environment enabling basic and applied life sciences research.
Novel co-culture protocols have been developed that establish true vascular monolayers in communication with tissue cells. Human cells grown in SynVivo chips retain biological phenotypes that are similar to cells found in the tissues. Leading researchers have validated that cells grown in SynVivo chips more accurately reflect the tissue cells found inside the body than do cells grown using conventional culture techniques.
The successful coupling of digitized tissue imaging with silicon etching technologies allows SynVivo to design and manufacture microfluidic chips that can be adapted for a variety of uses. All chip designs incorporate ports for introduction of cells and reagents and for collecting effluent for analysis. They can accommodate virtually any analytical technology.
The SynVivo chip platform technology has been validated for multiple applications:
Tumor characterization, invasion, intravasation, extravasation
Drug transport across the blood-brain barrier, tight junctions, transporter proteins
Immune cell interactions, rolling, adhesion, and migration, cytokines
Heart, liver, lung and kidney models.
In addition, SynVivo’s capability to rapidly prototype custom chips allows the replication of unique features of any desired organ and tissue for disruptive applications. For more information, please refer to literature references describing the studies conducted with SynVivo technology. Our platform is protected by an extensive IP portfolio that covers broad use across multiple disease areas and tissue types.
SynVivo, LLC is a subsidiary of CFDRC - Learn more at www.synvivobio.com